VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)

In recent years, great progress has been made in understanding biology and pathogenesis of chronic lymphocytic leukemia. The key thing in disease pathogenesis is the apoptosis resistance of tumor cells. One of the main regulators of programmed cell death is the Bcl-2 family proteins. Important role...

Full description

Saved in:

Bibliographic Details
Main Author:	T. E. Byalik
Format:	Article
Language:	Russian
Published:	ABV-press 2018-07-01
Series:	Онкогематология
Subjects:	chronic lymphocytic leukemia venetoclax
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/286
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of venetoclax in relapsed/refractory chronic lymphocytic leukemia in Russia routine clinical practice
by: E. A. Dmitrieva, et al.
Published: (2024-09-01)

Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment
by: A. V. Rudakova, et al.
Published: (2020-04-01)

Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
by: Elżbieta Iskierka-Jażdżewska, et al.
Published: (2025-01-01)

A clinical case of the effective combined use of BCL-2 and PI3K inhibitors in the treatment of a patient with an unfavorable chronic lymphocytic leukemia with transformation into diffuse large B-cell lymphoma (Richter’s syndrome)
by: O. A. Rukavitsyn, et al.
Published: (2022-11-01)

Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia
by: I. V. Cherkashina, et al.
Published: (2025-03-01)

Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk
by: Anna Ewa Wolska-Washer, et al.
Published: (2025-01-01)

Meningeal involvement in chronic lymphocytic leukemia
by: S. N. Menshakova, et al.
Published: (2022-11-01)

Bendamustine: a new view on treatment of chronic lymphocytic leukemia
by: Ye. A. Nikitin
Published: (2022-11-01)

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025-06-01)

METABOLIC STATE OF BLOOD LYMPHOCYTES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOID LEUKEMIA
by: O. V. Smirnova, et al.
Published: (2014-07-01)

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
by: Mei Zhou, et al.
Published: (2025-07-01)

Comparative efficacy of chronic lymphocytic leukemia treatment with or without rituximab
by: E. A. Zenkova, et al.
Published: (2019-12-01)

Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach
by: Aditi Sharma, et al.
Published: (2025-06-01)

Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective
by: Tana Saiyin, et al.
Published: (2025-04-01)

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia
by: Yiming Cai, et al.
Published: (2025-07-01)

IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
by: M. N Khorobrykh, et al.
Published: (2014-07-01)

Venetoclax synergizes with Wnt/β-catenin inhibitor C-82 in acute myeloid leukemia by increasing the degradation of Mcl-1 protein
by: Mengya Pan, et al.
Published: (2025-05-01)

Immunological Synapse in the Biology of Chronic Lymphocytic Leukemia
by: DS Badmazhapova, et al.
Published: (2018-10-01)

Immunotherapy in chronic lymphocytic leukemia: advances and challenges
by: Pan Gao, et al.
Published: (2025-04-01)

Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study
by: Noelia Pérez-Gómez, et al.
Published: (2025-07-01)

PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia
by: O. N. Selyutina, et al.
Published: (2023-12-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

Treatment of elderly patients with acute myeloid leukemia: personal experience
by: L. T. Shimanovskaya, et al.
Published: (2024-12-01)

Chlorambucil effect on B lymphocites in the peripheral blood of patients with chronic lymphocytic leukemia: Cell ultrastructure investigation
by: Brajušković Goran R., et al.
Published: (2003-01-01)

The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients
by: NV Kurkina, et al.
Published: (2019-05-01)

Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01)

Atorvastatin influence on cardiac function and rhythm variability in patients with chronic lymphocytic leukemia in remission
by: B. B. Samura
Published: (2019-03-01)

FEATURES OF IMMUNOCOMPETENT CELLS IN THE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT PRIMARY DIAGNOSIS
by: N. V. Isaeva, et al.
Published: (2016-01-01)

Role of Patient’s Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia
by: VV Strugov, et al.
Published: (2016-04-01)

Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
by: Alaa Eldein Yahia, et al.
Published: (2025-01-01)

Value of circulating galectin-3 for prognosis of cardiovascular events in patients with chronic lymphocytic leukemia in remission
by: B. B. Samura, et al.
Published: (2014-12-01)

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01)

Myocardial contractility dysfunction in patients with chronic lymphocytic leukemia receiving chemotherapy and their treatment with enalapril
by: I. L. Davydkin, et al.
Published: (2020-03-01)

Evaluation of interleukin-6 level in patients with chronic lymphocytic leukemia and its correlation with the stage of the disease
by: Nuha Abd Ali Al-Sarai, et al.
Published: (2025-01-01)

Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities
by: Leiming Xia, et al.
Published: (2025-07-01)

Alemtuzumab in treatment of chronic lymphocytic leukemia
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Antioxidant Content Analysis of Microgreen Radish and Parsley and Evaluation of Their Antiproliferative Effects in Chronic Lymphocytic Leukemia Cells
by: Sena Tıraş, et al.
Published: (2025-06-01)

The Elevation and Impact of Peripheral Bile Acids in Chronic Lymphocytic Leukemia
by: Audrey L. Smith, et al.
Published: (2025-04-01)

Successful remission induction therapy with azacitidine and venetoclax for a treatment-naive elderly patient with ETP/myeloid mixed-phenotype acute leukemia: a case report
by: Kaikai Huang, et al.
Published: (2025-08-01)

Extranodal Manifestation of Chronic Lymphocytic Leukemia: A Case of Bilateral Breast Involvement
by: Ensiyeh Bahadoran, et al.
Published: (2025-06-01)